M. E. Blair Holbein

The University of Texas Southwestern Medical Center

MedicinePharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis”.

IL‐1 receptor antagonist plus pentoxifylline and zinc for severe alcohol‐associated hepatitis

Hepatology(2022)10.1002/hep.32478

N/A

2.2DataRank · unranked

102 citations

Mack C. Mitchell, Craig J. McClain, Srinivasan Dasarathy, Bruce Barton, Arthur J. McCullough +9 more

Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic

Journal of Clinical and Translational Science(2021)10.1017/cts.2021.15

N/A

0.664DataRank · unranked

11 citations

Jeanne Wright, M. E. Blair Holbein, Marlene Berro, Jennifer S. Brown, George A. Mashour +2 more

Experience, Perceptions, and Recommendations Concerning COVID-19–Related Clinical Research Adjustments

Journal of the National Comprehensive Cancer Network(2021)10.6004/jnccn.2020.7643

N/A

0DataRank · unranked

23 citations

Thomas Sheffield, Muhammad Shaalan Beg, Erin L. Williams, Valerie L. Clark, Yang Xie +4 more

Longitudinal Experience With and Impressions of COVID-19–Related Clinical Research Changes

JCO Oncology Practice(2021)10.1200/op.21.00169

N/A

0DataRank · unranked

8 citations

Valerie L. Clark, Thomas Sheffield, Muhammad Shaalan Beg, Yang Xie, M. E. Blair Holbein +4 more